fda warning letters compounded semaglutide 2024 2025 Warns Novo Nordisk on Unreported Deaths FDA warns against compounded GLP-1

Changes in the asthma prevalence between 1981 and 1988 were studied in the US National Health Interview Survey (NHIS) in 0- to 17-year-old children (Weitzman et al., 1992)

The liposomal form involves encapsulating the active ingredients in liposomes (fatty substances) to prevent them from being eliminated by gastric juices or digestive enzymes, giving it greater stability and bioavailability

Immunogenicity: The FDA classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding (immunogenicity, impurities, and insufficient safety evidence for suggested administration routes)

NEFAs, n = 33 mice

Recognizing Demographical Limitations : The authors explicitly note that because this mechanistic trial was executed solely in male mouse models, future trials must include female subjects to verify if the same microbiome-endocannabinoid pathway regulates mood across both sexes

semaglutide with B12 Vitamin B12 (cyanocobalamin or methylcobalamin) is probably the most common additive in compounded semaglutide